Alvotech Could Upend Expectations For US Humira Biosimilars
Founder And Chairman Robert Wessman Discusses Firm’s Adalimumab Prospects
In the second part of an exclusive two-part interview with Generics Bulletin, Alvotech founder and chairman Robert Wessman sets out the firm’s expectations for its rival to Humira, as Alvotech continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.
